News

Pharmaceutical Technology on MSN4d
Veraxa and OmniAb to develop bispecific ADC tumour programme
Veraxa Biotech has entered a joint discovery partnership with OmniAb tp develop a bispecific antibody drug conjugate (bsADC) ...
Seeking Alpha5d
CStone Presents Preclinical Results of CS2011 (EGFR/HER3 bispecific antibody), CS5007 (EGFR/HER3 bispecific ADC), CS5005 (SSTR2 ADC) and CS5006 (ITGB4 ADC) at 2025 AACR
CS5007 (EGFR/HER3 bispecific ADC): CS5007 is a bispecific ADC targeting both EGFR and HER3, developed with CStone's proprietary ADC platform. It is composed of EGFR/HER3 bispecific antibody ...
Taiwan News2d
BioDlink Congratulates Junshi Biosciences on IND Approval of JS212, a Bispecific ADC Therapeutic Candidate
As a bispecific ADC, JS212 has a key advantage over traditional ADCs that only target one protein: it can attack tumors via either EGFR or HER3, potentially increasing its effectiveness against a ...
Pharmabiz5d
Veraxa Biotech inks co-discovery alliance with OmniAb for novel bispecific ADC programme
Veraxa Biotech AG (Veraxa), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp., announced a co-discovery alliance with OmniAb, ...
ksn.com13d
2025 AACR | Innovent Presents Preclinical Data of Multiple Novel Molecules including Bispecific and Tri-specific Antibodies and Bispecific ADCs
IBI3014 is a bispecific ADC targeting TROP2 and PD-L1. Its dual mechanism integrates TROP2-directed tumor killing with PD-L1 immune checkpoint blockade, enhancing immunogenic cell death and T cell ...
FOX40 News13d
2025 AACR | Innovent Presents Preclinical Data of Multiple Novel Molecules including Bispecific and Tri-specific Antibodies and Bispecific ADCs
SAN FRANCISCO and SUZHOU, China, April 27, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that ...